Kidney Transplant Stem Cell Trial: What the Results Show
Key Takeaways A phase 3 trial led by the University of Wisconsin-Madison kept 15 of 20 treated recipients off anti-rejection drugs for over two years. The therapy uses blood-forming stem cells from the same sibling who donates the kidney. None of the 20 treated recipients developed graft-versus-host disease. Only closely
October 7, 2026
No Comments
